Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis
Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N, Taran FA, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching P, Fehm TN, Kolberg HC, Overkamp F, Schneeweiss A, Tesch H (2019)
Publication Type: Journal article
Publication year: 2019
Journal
Book Volume: 40
Pages Range: 433-444
Journal Issue: 7
DOI: 10.1055/a-0982-9861
Abstract
For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called postneoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.
Authors with CRIS profile
Naiba Nabieva
Department of Obstetrics and Gynaecology
Peter Fasching
Professur für Translationale Frauenheilkunde und Geburtshilfe
Involved external institutions
OncoConsult
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
ClinSol GmbH & Co.KG
Germany (DE)
Klinikum rechts der Isar
Germany (DE)
Eberhard Karls Universität Tübingen
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Marienhospital Bottrop
Germany (DE)
Agaplesion Markus Krankenhaus
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
Germany (DE)
Universitätsklinikum Düsseldorf
Germany (DE)
ClinSol GmbH & Co.KG
Germany (DE)
Klinikum rechts der Isar
Germany (DE)
Eberhard Karls Universität Tübingen
Germany (DE)
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universitätsklinikum Würzburg
Germany (DE)
Universitätsklinikum Hamburg-Eppendorf (UKE)
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Marienhospital Bottrop
Germany (DE)
Agaplesion Markus Krankenhaus
Germany (DE)
Universitätsklinikum Heidelberg
Germany (DE)
How to cite
APA:
Hartkopf, A.D., Müller, V., Wöckel, A., Lux, M.P., Janni, W., Nabieva, N.,... Tesch, H. (2019). Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis. TumorDiagnostik & Therapie, 40(7), 433-444. https://doi.org/10.1055/a-0982-9861
MLA:
Hartkopf, Andreas D., et al. "Update Mammakarzinom 2019 Teil 1 – Implementierung der Ergebnisse neuer Studienkonzepte beim frühen Mammakarzinom in die klinische Praxis." TumorDiagnostik & Therapie 40.7 (2019): 433-444.
BibTeX: Download